Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308363 | 0.81 | — | — | |
| SCHEMBL11918302 | 0.81 | — | — | |
| SCHEMBL30662330 | 0.77 | TSHR (0.39) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL2619499 | 0.75 | — | — | |
| SCHEMBL9326262 | 0.75 | — | — | |
| SCHEMBL13226901 | 0.74 | TAS1R3 (0.37) | BLMLMNAAPEX1NPSR1TP53 | |
| SCHEMBL13703288 | 0.74 | TAS1R3 (0.37) | BLMLMNAAPEX1NPSR1TP53 | |
| SCHEMBL9475391 | 0.74 | CHRNB2 (0.34) | — | |
| SCHEMBL12044505 | 0.73 | GRIK1 (0.38) | BLMLMNATDP1ALDH1A1CYP2D6 | |
| SCHEMBL2611675 | 0.73 | ALDH1A1 (0.31) | TSHRTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197646-A1 | SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197646-A1 | SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197646-A1 | SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS | TARBP1, TSNAX, TARDBP | TSHR 3171/4885GABRR1 1841/4885GABRR2 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.